EP1173145A1 - Composition for cosmetic and dermatological skin care - Google Patents
Composition for cosmetic and dermatological skin careInfo
- Publication number
- EP1173145A1 EP1173145A1 EP00910486A EP00910486A EP1173145A1 EP 1173145 A1 EP1173145 A1 EP 1173145A1 EP 00910486 A EP00910486 A EP 00910486A EP 00910486 A EP00910486 A EP 00910486A EP 1173145 A1 EP1173145 A1 EP 1173145A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- skin
- composition according
- weight
- composition
- proteinase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/001—Preparations for care of the lips
Definitions
- composition for cosmetic and dermatological care of the skin Composition for cosmetic and dermatological care of the skin
- the present invention relates to a composition for cosmetic and dermatological care of the skin, this composition containing at least one oxidoreductase and at least one proteinase inhibitor.
- the compositions according to the invention can be present, for example, as a cream, lotion, emulsion, gel, powder, plaster or in another suitable form.
- the task of the skin as an organ enveloping the organism consists in sealing and mediating functions against the environment.
- Various biochemical and bio-physical systems serve to maintain the integrity of this exposed organ.
- an immune system protects the skin from damage caused by pathogenic microorganisms
- the melanin-forming system regulates pigmentation and protects the skin from radiation damage
- a lipid system produces lipid micelles that contain the transdermal water loss
- regulated keratin synthesis provides the mechanically resistant horny layer.
- the systems mentioned are based on complex chemical processes, the course of which is kept in motion by enzymes and regulated by enzyme inhibitors. Even a slight inhibition or disinhibition of these biochemical systems manifests itself in noticeable changes in the skin.
- the visible and tangible condition of the skin is, however, a yardstick for beauty, health and youth; Preserving it is a general goal of nourishing cosmetics.
- the human skin usually reacts to exogenous, ie external stress factors such as UV radiation, ozone or other harmful substances present in the air (environmental pollution) with slight or severe irritation. nen.
- the skin is damaged by the released in irritation reactions of oxygen radicals and non-spe ⁇ -specific proteases.
- this can have a negative effect on the appearance or the elasticity or the barrier functions of the skin.
- excess mobilized body proteinases such as tryptases, elastases, collagenases and cathepsins, can attack the skin and in particular its structural proteins such as collagen and elastin.
- EP 0 532 465 discloses the use of selected protein fractions obtained from legume seeds as a proteinase inhibitor for the cosmetic and dermatological care of the skin and for the treatment of inflammatory skin diseases.
- a combination of an oxidoreductase together with a proteinase inhibitor is excellent for the cosmetic and dermatological care of the skin and for the treatment of inflammatory skin diseases and in particular for protection against damage to the skin by pollutants in the atmosphere, such as ozone and nitrogen oxides , Dust particles etc., as well as UV rays and detergents, is suitable, the protection against the damage caused by ozone being in the foreground.
- pollutants in the atmosphere such as ozone and nitrogen oxides , Dust particles etc., as well as UV rays and detergents
- the combination of a biotechnologically produced, purified oxidoreductase with a proteinase inhibitor, preferably a proteinase inhibitor obtained from legume seeds and containing selected protein fractions, is particularly suitable.
- the present invention relates to a composition which is suitable for the cosmetic and dermatological care of the skin, in particular for protecting the skin against damage caused by an increased ozone concentration in the atmosphere and its subsequent reactions, characterized in that this composition comprises at least one oxidoreductase and contains at least one proteinase inhibitor.
- the present invention also relates to the use of a composition which contains at least one oxidoreductase and at least one proteinase inhibitor for the cosmetic and dermatological care of the skin and for the treatment of inflammatory skin reactions, in particular for protection against damage to the skin by pollutants in the atmosphere (ozone , Nitrogen oxides, dust particles etc.), UV rays and detergents.
- pollutants in the atmosphere ozone , Nitrogen oxides, dust particles etc.
- the invention further relates to a preparation which is preferably a cream, lotion, emulsion, a gel, powder, plaster or another suitable cosmetic form of application which contains a composition according to the invention.
- the weight ratio of the oxidoreductase to the proteinase inhibitor is generally preferably in the range from 20: 1 to 1:20, preferably in the range from 10: 1 to 1:10 and in particular from 6: 1 to 1: 6.
- the substances according to the invention are expediently used in a skin-friendly vehicle, for example as a cream, lotion, gel, face mask, powder or plaster.
- the acid value is preferably in the pH range from 5.5 to 9.
- the finished preparations generally contain 0.001 to 1% by weight, preferably 0.01 to 0.5% by weight, preferably 0.05 to 0.5% by weight , the composition according to the invention as dry matter, calculated on the total weight (100% by weight) of the finished product.
- the preparations can also contain larger amounts, for example up to about 2.5% by weight, preferably 0.001 to 2.2% by weight, calculated on the total weight of the finished product.
- the upper limit is not critical.
- plasters for transdermal application of a preparation according to the invention can contain up to 10% by weight, preferably up to 5% by weight, of the composition according to the invention (always calculated as dry matter) calculated on the total weight (100% by weight) of the patch -Finished preparation included.
- the composition preferably contains the proteinase inhibitor in an amount of at least 0.005% by weight, preferably at least 0.01% by weight, calculated on the total weight of the composition.
- stable active ingredient concentrates which contain the combination according to the invention of at least one oxidoreductase and at least one proteinase inhibitor, with an active ingredient content as dry substance of 0.01 to 10 wt. %, preferably from 0.1% by weight to 5% by weight, can be prepared by dissolving the combination of active substances according to the invention in water and with the addition of a water-soluble preservative, such as, for example, methyl p-oxybenzoate, to prevent microbial growth Growth and one polyhydric alcohol, such as ethylene glycol or propylene glycol, to stabilize the active ingredient.
- a water-soluble preservative such as, for example, methyl p-oxybenzoate
- polyhydric alcohol such as ethylene glycol or propylene glycol
- Oxidoreductases used according to the invention are able to intercept or neutralize free oxygen radicals.
- Oxidoreductases are preferably produced biotechnologically. This production is known per se and, for example, in Appl. Microbiol. Biotechnol. (1987) 26, pp. 531-536.
- Oxidoreductases are, for example, lactoperoxidase, glutathione oxidase, glutathione reductase, glutathione peroxidase, superoxide dismutase, thiol oxidase, peroxidase, thioredoxin reductase, cytochrome c reductase, cytochrome oxidase. Lactoperoxidase, glutathione peroxidase and superoxide dismutase are preferred.
- the proteinase inhibitor to be used according to the invention is capable of rendering non-specific proteinases ineffective.
- the proteinase inhibitor to be used according to the invention is preferably a protein fraction containing at least one protein which a) was isolated from legume seeds, and b) at least one band in polyacrylamide gel electrophoresis with sodium dodecyl sulfate, c) molecular weights in the range from 3,000 to 30 minutes. 000 g / mol, d) a total nitrogen content of 14% to 20% and
- Proteins or proteinase inhibitors to be used according to the invention are preferably produced from legume seeds, for example from bean species, such as, for example, Phaseolus angularis, Phaseolus lunatus, Phaseolus aureus, Phaseolus vulgaris, Phaseolus coccineus, Phaseolus limensis, from pea species such as, for example, La thyrus odora tus, from soybeans Glycine max and Glvcine hispida, from peanut Arachis hypogaea and from seeds of tropical legumes of the genera Cajanus, Dolichus, Vigna and Vi cia. Protein fractions which have been produced from legume seeds soya or lima beans are preferred.
- composition according to the invention is preferably used in day creams, after-sun creams, in products for the treatment of dry, poorly elastic skin, for skin which is sensitive to harmful substances of the environment, such as, for example, ozone, or also for the regenerative treatment of tired, aging or stressed skin, used.
- composition according to the invention is preferably produced on an aqueous basis and can contain further additives such as solvents, preservatives, buffers, antioxidants and / or dyes.
- additives are known per se and are listed, for example, in the CTFA Dictionary.
- Preferred solvents are, for example, polyglycols or polyalcohols, preferably glycerol.
- Preferred preservatives are, for example, phenoxyethanol, methylparaben, propylparaben, ethylparaben or butylparaben, such as are commercially available, for example, as a mixture under the brand name Phenonip®.
- Other additives are known to the person skilled in the art.
- composition according to the invention can also be combined with active ingredients, such as sunscreens, moisturizers, skin-revitalizing active ingredients, barrier agents and / or self-tanners.
- active ingredients such as sunscreens, moisturizers, skin-revitalizing active ingredients, barrier agents and / or self-tanners.
- active ingredients are known per se.
- Sunscreens include octyl methoxycinnamate, butyl methoxydibenzoylmethane, benzophenone, titanium dioxide, zinc oxide, and related compounds.
- Humectants are, for example, glycosammoglycans, hyaluronic acid and other polysaccharides, proteins and protein hydrolysates such as collagen, elastm, wheat protein hydrolysates and similar compounds, urea, glycols and polyglycols.
- Skin revitalizing active ingredients include vitamins, alpha-hydroxy acids, amino acids and related compounds.
- Barriers are, for example, ceramides, free fatty acids, sterols, triglycerides.
- Self-tanning agents are, for example, dihydroxyacetone or erythrulose.
- Preparation of a make-up lotion a) The additives of the substances listed in Table 1 under A) are heated in a mixer to 70 ° C. and mixed well. The substances listed in Table 1 above under B) are then mixed in a mixer at a temperature of 75 ° C. b) The mixture of components B) is then slowly added to mixture A with stirring at 70 ° C. and, after the addition has ended, cooled to 50 ° C., homogenized and then cooled to 30 ° C. Then the dye is added and stirred cold. You get a make-up lotion with a very good effect.
- phase A) The components of phase A) are mixed and heated to 70 ° C. while mixing.
- the components of phase B) are heated to 75 ° C.
- phase B) is added to the mixture of phase A) obtained with stirring.
- the mixture is then cooled to 50 ° C., homogenized and further cooled to 30 ° C.
- Preparation of a regenerative gel a) Components 2 to 6 of phase A) are dissolved in water. Components 7 and 8 of phase B) are added to thicken and neutralize the mixture obtained, a gel being obtained.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a composition which is suitable for cosmetic and dermatological skin care. In particular, said composition is to be used to protect the skin against damage by an increased ozone concentration in the atmosphere and against secondary reactions thereto. The composition contains at least one oxidoreductase and at least one proteinase inhibitor, whereby the weight ratio of the oxidoreductase to the proteinase inhibitor is preferably between 20: 1 and 1: 20, preferably between 10: 1 and 1: 10 and in particular, between 6: 1 and 1: 6.
Description
Zusammensetzung für die kosmetische und dermatologische Pflege der HautComposition for cosmetic and dermatological care of the skin
Die vorliegende Erfindung betrifft eine Zusammensetzung zur kosmetischen und dermatologischen Pflege der Haut, wobei diese Zusammensetzung mindestens eine Oxidoreduktase und mindestens einen Proteinase-Inhibitor enthält. Die erfin- dungsgemässen Zusammensetzungen können beispielsweise als Creme, Lotion, Emulsion, Gel, Puder, Pflaster oder in einer anderen geeigneten Form vorliegen.The present invention relates to a composition for cosmetic and dermatological care of the skin, this composition containing at least one oxidoreductase and at least one proteinase inhibitor. The compositions according to the invention can be present, for example, as a cream, lotion, emulsion, gel, powder, plaster or in another suitable form.
Die Aufgabe der Haut als ein den Organismus umhüllendes Organ besteht in abdichtenden und vermittelnden Funktionen gegenüber der Umwelt. Verschiedene biochemische und bio- physikalische Systeme dienen der Aufrechterhaltung der Integrität dieses exponierten Organs. Beispielsweise schützt ein Immunsystem die Haut vor Schäden durch pathogene Mikroorganismen, das Melanin bildende System regelt die Pigmentierung und bewahrt die Haut vor Strahlenschäden, ein Lipidsystem produziert Lipidmizellen, die den transdermalen Wasserverlust eindämmen, und eine geregelte Keratinsynthese liefert die mechanisch widerstandsfähige Hornschicht. Den genannten Systemen liegen komplexe chemische Prozesse zugrunde, deren Ablauf unter anderem durch Enzyme in Gang ge- halten und durch Enzyminhibitoren geregelt wird. Bereits eine geringfügige Hemmung oder Enthemmung dieser biochemischen Systeme äussert sich in spürbaren Veränderungen der Haut. Der sichtbare und fühlbare Zustand der Haut gilt jedoch als Massstab für Schönheit, Gesundheit und Jugend; ihn zu erhalten ist ein generelles Ziel pflegender Kosmetik.The task of the skin as an organ enveloping the organism consists in sealing and mediating functions against the environment. Various biochemical and bio-physical systems serve to maintain the integrity of this exposed organ. For example, an immune system protects the skin from damage caused by pathogenic microorganisms, the melanin-forming system regulates pigmentation and protects the skin from radiation damage, a lipid system produces lipid micelles that contain the transdermal water loss, and regulated keratin synthesis provides the mechanically resistant horny layer. The systems mentioned are based on complex chemical processes, the course of which is kept in motion by enzymes and regulated by enzyme inhibitors. Even a slight inhibition or disinhibition of these biochemical systems manifests itself in noticeable changes in the skin. The visible and tangible condition of the skin is, however, a yardstick for beauty, health and youth; Preserving it is a general goal of nourishing cosmetics.
Die menschliche Haut reagiert in der Regel auf exogene, d.h. externe Stressfaktoren, wie UV-Strahlung, Ozon oder andere in der Luft vorhandene schädliche Substanzen (Um- weltverschmutzung) mit leichten oder schwereren Irritatio-
nen. Insbesondere wird die Haut durch die in Irritationsreaktionen freigesetzten Sauerstoffradikale und nicht-spe¬ zifischen Proteinasen geschädigt. Dies kann beispielsweise das Aussehen oder die Elastizität oder die Barrierefunktio- nen der Haut negativ beeinflussen. So können bei entzündlichen Prozessen und Immunreaktionen im Überschuss mobilisierte körpereigene Proteinasen, wie zum Beispiel Tryptasen, Elastasen, Kollagenasen und Cathepsine, die Haut und im besonderen deren Strukturproteine wie Collagen und Elastin angreifen.The human skin usually reacts to exogenous, ie external stress factors such as UV radiation, ozone or other harmful substances present in the air (environmental pollution) with slight or severe irritation. nen. In particular, the skin is damaged by the released in irritation reactions of oxygen radicals and non-spe ¬-specific proteases. For example, this can have a negative effect on the appearance or the elasticity or the barrier functions of the skin. In inflammatory processes and immune reactions, excess mobilized body proteinases, such as tryptases, elastases, collagenases and cathepsins, can attack the skin and in particular its structural proteins such as collagen and elastin.
Aus der EP 0 532 465 ist die Verwendung von aus Leguminose- samen gewonnenen ausgewählten Proteinfraktionen als Pro- teinaseinhibitor für die kosmetische und dermatologische Pflege der Haut und zur Behandlung entzündlicher Hauterkrankungen bekannt.EP 0 532 465 discloses the use of selected protein fractions obtained from legume seeds as a proteinase inhibitor for the cosmetic and dermatological care of the skin and for the treatment of inflammatory skin diseases.
Es wurde nun überraschenderweise gefunden, dass eine Kombination einer Oxidoreduktase zusammen mit einem Proteinase- inhibitor hervorragend für die kosmetische und dermatologische Pflege der Haut und zur Behandlung entzündlicher Hauterkrankungen und insbesondere zum Schutz gegen die Schädigung der Haut durch Schadstoffe in der Atmosphäre, wie Ozon, Stickoxide, Staubpartikel etc., sowie UV-Strahlen und Detergentien, geeignet ist, wobei der Schutz gegen die Schädigung durch Ozon im Vordergrund steht. Insbesondere geeignet ist die Kombination einer biotechnologisch hergestellten gereinigten Oxidoreduktase mit einem Proteinase- inhibitor, vorzugsweise einem aus Leguminosesamen gewon- nenen, ausgewählten Proteinfraktionen enthaltenden, Pro- teinaseinhibitor . Menschliche Keratinocyten, welche in einer in vivo Studie atmosphärischem Ozon ausgesetzt wurden, wiesen eine erhöhte Überlebensfähigkeit auf. Klinische Studien an Probanden mit als Folge von Detergentien und UV- Strahlung gereizter bzw. entzündeter und trockener Haut,
zeigten bei Applikation der erfindungsgemässen Zusammensetzung eine erhebliche Verbesserung der Hautreizung. Analogerweise zeigten in vivo Untersuchungen durch Messung der Hautelastizität erhebliche Verbesserung der Elastizität und der Widerstandskraft der Haut.It has now surprisingly been found that a combination of an oxidoreductase together with a proteinase inhibitor is excellent for the cosmetic and dermatological care of the skin and for the treatment of inflammatory skin diseases and in particular for protection against damage to the skin by pollutants in the atmosphere, such as ozone and nitrogen oxides , Dust particles etc., as well as UV rays and detergents, is suitable, the protection against the damage caused by ozone being in the foreground. The combination of a biotechnologically produced, purified oxidoreductase with a proteinase inhibitor, preferably a proteinase inhibitor obtained from legume seeds and containing selected protein fractions, is particularly suitable. Human keratinocytes, which were exposed to atmospheric ozone in an in vivo study, showed increased survivability. Clinical studies on subjects with skin irritated or inflamed and dry as a result of detergents and UV radiation, showed a considerable improvement in skin irritation when the composition according to the invention was applied. Similarly, in vivo studies by measuring skin elasticity showed significant improvements in skin elasticity and resistance.
Die vorliegende Erfindung ist in den Patentansprüchen definiert. Insbesondere betrifft die vorliegende Erfindung eine Zusammensetzung, welche für die kosmetische und dermatolo- gische Pflege der Haut geeignet ist, insbesondere zum Schutz der Haut gegen deren Schädigung durch eine erhöhte Ozonkonzentration in der Atmosphäre und deren Folgereaktionen, dadurch gekennzeichnet, dass diese Zusammensetzung mindestens eine Oxidoreduktase und mindestens einen Proteinase-Inhibitor enthält.The present invention is defined in the claims. In particular, the present invention relates to a composition which is suitable for the cosmetic and dermatological care of the skin, in particular for protecting the skin against damage caused by an increased ozone concentration in the atmosphere and its subsequent reactions, characterized in that this composition comprises at least one oxidoreductase and contains at least one proteinase inhibitor.
Die vorliegende Erfindung betrifft auch die Verwendung einer Zusammensetzung, welche mindestens eine Oxidoreduktase und mindestens einen Proteinase-Inhibitor enthält, zur kosmetischen und dermatologischen Pflege der Haut und zur Behandlung entzündlicher Hautreaktionen, insbesondere zum Schutz gegen die Schädigung der Haut durch Schadstoffe in der Atmosphäre (Ozon, Stickoxide, Staubpartikel etc.), UV- Strahlen und Detergentien.The present invention also relates to the use of a composition which contains at least one oxidoreductase and at least one proteinase inhibitor for the cosmetic and dermatological care of the skin and for the treatment of inflammatory skin reactions, in particular for protection against damage to the skin by pollutants in the atmosphere (ozone , Nitrogen oxides, dust particles etc.), UV rays and detergents.
Die Erfindung betrifft im weiteren auch eine Zubereitung, welche vorzugsweise eine Creme, Lotion, Emulsion, ein Gel, Puders, Pflaster oder eine andere geeignete kosmetische Applikationsform darstellt, welche eine erfindungsgemässe Zusammensetzung enthält.The invention further relates to a preparation which is preferably a cream, lotion, emulsion, a gel, powder, plaster or another suitable cosmetic form of application which contains a composition according to the invention.
Das Gewichtsverhältnis der Oxidoreduktase zum Proteinase- Inhibitor liegt in der Regel vorzugsweise im Bereich von 20:1 bis 1:20, vorzugsweise im Bereich von 10 : 1 bis 1 : 10 und insbesondere von 6 : 1 bis 1 : 6.
Zur dermatologischen und kosmetischen Anwendung werden die erfindungsgemassen Substanzen zweckmassigerweise in einem hautfreundlichen Vehikel, beispielsweise als Creme, Lotion, Gel, Gesichtsmaske, Puder oder Pflaster eingesetzt. Der Säurewert ist dabei vorzugsweise im pH-Bereich von 5.5 - 9. Mit Ausnahme der Pflaster enthalten die fertigen Präparate in der Regel 0,001 bis 1 Gew.-%, vorzugsweise 0.01 bis 0.5 Gew.-%, vorzugsweise 0.05 bis 0.5 Gew.-%, der erfindungs- gemassen Zusammensetzung als Trockensubstanz, berechnet auf das Gesamtgewicht (100 Gew.-%) des Fertigpraparats . Die Präparate können aber auch grossere Mengen enthalten, beispielsweise bis etwa 2.5 Gew.-%, vorzugsweise 0.001 bis 2.2 Gew.-%, berechnet auf das Gesamtgewicht des Fert gprapa- rats. Die obere Grenze ist nicht kritisch. Pflaster zur transdermalen Applikation eines erfindungsgemassen Präparats können hingegen bis zu 10 Gew.-%, vorzugsweise bis zu 5 Gew.-%, der erfindungsgemassen Zusammensetzung (immer berechnet als Trockensubstanz) berechnet auf das Gesamt- gewicht (100 Gew.-%) des Pflaster-Fertigpraparats enthalten. Vorzugsweise enthalt die Zusammensetzung den Proteinase-Inhibitor in einer Menge von mindestens 0.005 Gew.-%, vorzugsweise mindestens 0.01 Gew.-%, berechnet auf das Gesamtgewicht der Zusammensetzung. Um die Formulierung flussiger oder halbfester Zubereitungen zu erleichtern, können in einem ersten Schritt gut dosierbare, stabile Wirkstoffkonzentrate, welche die erfindungsgemasse Kombination von mindestens einer Oxidoreduktase und mindestens einem Proteinase-Inhibitor enthalten, mit einem Gehalt an Wirkstoff als Trockensubstanz von 0.01 bis 10 Gew.-%, vorzugsweise von 0.1 Gew.-% bis 5 Gew.-%, hergestellt werden, indem man die erfindungsgemasse Wirkstoffkombi- nation in Wasser lost und mit einem Zusatz eines wasserlöslichen Konservierungsmittels, wie zum Beispiel Methyl-p- oxybenzoat, zur Verhütung mikrobiellen Wachstums und eines
mehrwertigen Alkohols, wie zum Beispiel Ethylenglykol oder Propylenglykol, zur WirkstoffStabilisierung, versieht.The weight ratio of the oxidoreductase to the proteinase inhibitor is generally preferably in the range from 20: 1 to 1:20, preferably in the range from 10: 1 to 1:10 and in particular from 6: 1 to 1: 6. For dermatological and cosmetic use, the substances according to the invention are expediently used in a skin-friendly vehicle, for example as a cream, lotion, gel, face mask, powder or plaster. The acid value is preferably in the pH range from 5.5 to 9. With the exception of the plasters, the finished preparations generally contain 0.001 to 1% by weight, preferably 0.01 to 0.5% by weight, preferably 0.05 to 0.5% by weight , the composition according to the invention as dry matter, calculated on the total weight (100% by weight) of the finished product. However, the preparations can also contain larger amounts, for example up to about 2.5% by weight, preferably 0.001 to 2.2% by weight, calculated on the total weight of the finished product. The upper limit is not critical. However, plasters for transdermal application of a preparation according to the invention can contain up to 10% by weight, preferably up to 5% by weight, of the composition according to the invention (always calculated as dry matter) calculated on the total weight (100% by weight) of the patch -Finished preparation included. The composition preferably contains the proteinase inhibitor in an amount of at least 0.005% by weight, preferably at least 0.01% by weight, calculated on the total weight of the composition. In order to facilitate the formulation of liquid or semi-solid preparations, in a first step, well-dosed, stable active ingredient concentrates which contain the combination according to the invention of at least one oxidoreductase and at least one proteinase inhibitor, with an active ingredient content as dry substance of 0.01 to 10 wt. %, preferably from 0.1% by weight to 5% by weight, can be prepared by dissolving the combination of active substances according to the invention in water and with the addition of a water-soluble preservative, such as, for example, methyl p-oxybenzoate, to prevent microbial growth Growth and one polyhydric alcohol, such as ethylene glycol or propylene glycol, to stabilize the active ingredient.
Die erfindungsgemäss verwendeten Oxidoreduktasen sind in der Lage, freie Sauerstoffradikale abzufangen bzw. zu neutralisieren. Oxidoreduktasen werden vorzugsweise biotechnologisch hergestellt. Diese Herstellung ist an sich bekannt und beispielsweise in Appl . Microbiol. Biotechnol. (1987) 26, S. 531-536 beschrieben. Oxidoreduktasen sind beispielsweise Lactoperoxidase, Glutathion Oxidase, Glutathion Reductase, Glutathion Peroxidase, Superoxid Dismuta- se, Thiol Oxidase, Peroxidase, Thioredoxin Reductase, Cyto- chrom c Reductase, Cytochrom Oxidase. Bevorzugt sind Lactoperoxidase, Glutathion Peroxidase und Superoxid Dismutase.The oxidoreductases used according to the invention are able to intercept or neutralize free oxygen radicals. Oxidoreductases are preferably produced biotechnologically. This production is known per se and, for example, in Appl. Microbiol. Biotechnol. (1987) 26, pp. 531-536. Oxidoreductases are, for example, lactoperoxidase, glutathione oxidase, glutathione reductase, glutathione peroxidase, superoxide dismutase, thiol oxidase, peroxidase, thioredoxin reductase, cytochrome c reductase, cytochrome oxidase. Lactoperoxidase, glutathione peroxidase and superoxide dismutase are preferred.
Der erfindungsgemäss zu verwendende Proteinase-Inhibitor ist in der Lage nicht-spezifische Proteinasen unwirksam zu machen. Der erfindungsgemäss zu verwendende Proteinase-Inhibitor ist vorzugsweise eine Proteinfraktion enthaltend mindestens ein Protein, welches a) aus Leguminosensamen isoliert wurde, und b) mindestens eine Bande in der Polyacrylamidgelelektro- phorese mit Natriumdodecylsulfat , c) Molekularmassen im Bereich von 3 '000 bis 30 '000 g/Mol, d) einen Gehalt an Gesamtstickstoff von 14% bis 20% undThe proteinase inhibitor to be used according to the invention is capable of rendering non-specific proteinases ineffective. The proteinase inhibitor to be used according to the invention is preferably a protein fraction containing at least one protein which a) was isolated from legume seeds, and b) at least one band in polyacrylamide gel electrophoresis with sodium dodecyl sulfate, c) molecular weights in the range from 3,000 to 30 minutes. 000 g / mol, d) a total nitrogen content of 14% to 20% and
Aminostickstoff von 1 % bis 2% bezogen auf den Proteingehalt, e) Löslichkeit in Wasser und wässrigen Elektrolytlösungen und Unlöslichkeit in Ethanol und Aceton, f) starke Ausfällung in wässriger Lösung nach Zusatz vonAmino nitrogen from 1% to 2% based on the protein content, e) solubility in water and aqueous electrolyte solutions and insolubility in ethanol and acetone, f) strong precipitation in aqueous solution after the addition of
Trichloressigsäure, Sulfosalicylsäure, Pikrinsäure oderTrichloroacetic acid, sulfosalicylic acid, picric acid or
Benzethoniumchlorid, und g) Hemmung von Proteinasen, aufweist. Solche bevorzugte Proteinase-Inhibitoren sind beispielsweise in der EP 0 532 465 beschrieben.
Erfindungsgemäss zu verwendende Proteine bzw. Proteinase- Inhibitoren sind vorzugsweise aus Leguminosensamen hergestellt, beispielsweise aus Bohnenarten, wie zum Beispiel Phaseolus angularis, Phaseolus lunatus , Phaseolus aureus , Phaseolus vulgaris , Phaseolus coccineus , Phaseolus limen- sis, aus Erbsenarten wie zum Beispiel La thyrus odora tus, aus Soyabohnen Glycine max und Glvcine hispida, aus Erdnuss Arachis hypogaea sowie aus Samen tropischer Leguminosen der Gattungen Cajanus , Dolichus , Vigna und Vi cia . Bevorzugt sind Proteinfraktionen, welche aus Leguminosensamen Soya- oder Limabohnen hergestellt wurden.Benzethonium chloride, and g) inhibition of proteinases. Such preferred proteinase inhibitors are described, for example, in EP 0 532 465. Proteins or proteinase inhibitors to be used according to the invention are preferably produced from legume seeds, for example from bean species, such as, for example, Phaseolus angularis, Phaseolus lunatus, Phaseolus aureus, Phaseolus vulgaris, Phaseolus coccineus, Phaseolus limensis, from pea species such as, for example, La thyrus odora tus, from soybeans Glycine max and Glvcine hispida, from peanut Arachis hypogaea and from seeds of tropical legumes of the genera Cajanus, Dolichus, Vigna and Vi cia. Protein fractions which have been produced from legume seeds soya or lima beans are preferred.
Die erfindungsgemasse Zusammensetzung wird vorzugsweise in Tagescremen, After-sun-cremen, in Produkten für die Behandlung von trockener wenig elastischer Haut, für Haut, welche empfindlich auf schädliche Stoffe der Umwelt, wie beispielsweise Ozon, reagiert oder auch zur regenerativen Behandlung müder, alternder oder gestresster Haut, einge- setzt.The composition according to the invention is preferably used in day creams, after-sun creams, in products for the treatment of dry, poorly elastic skin, for skin which is sensitive to harmful substances of the environment, such as, for example, ozone, or also for the regenerative treatment of tired, aging or stressed skin, used.
Die erfindungsgemasse Zusammensetzung wird vorzugsweise auf wässriger Basis hergestellt und kann weitere Zusatzstoffe wie Lösungsmittel, Konservierungsmittel, Buffer, Antioxi- dantien und/oder Farbstoffe enthalten. Solche Zusatzstoffe sind an sich bekannt und beispielsweise im CTFA Dictionary aufgeführt. Bevorzugte Lösungsmittel sind beispielsweise Polyglykole oder Polyalkohole, vorzugsweise Glycerin. Bevorzugte Konservierungsmittel sind beispielsweise Phenoxy- ethanol, Methylparaben, Propylparaben, Ethylparaben oder Butylparaben, wie solche beispielsweise als Mischung unter dem Markennamen Phenonip® kommerziell erhaltlich sind. Weitere Zusatzstoffe sind dem Fachmann bekannt.
Die erfindungsgemasse Zusammensetzung kann auch mit Wirkstoffen, wie Sonnenschutzmittel, Feuchthaltemittel, Haut- revitalisierende Wirkstoffe, Barrieremittel und/oder Selbstbrauner kombiniert werden. Solche Wirkstoffe sind an sich bekannt. Sonnenschutzmittel sind beispielsweise Octyl Methoxycinnamat, Butyl Methoxydibenzoylmethan, Benzophenon, Titandioxid, Zinkoxid und verwandte Verbindungen. Feuchthaltemittel sind beispielsweise Glykosammoglykane, Hyalu- ronsaure und andere Polysaccharide, Proteine und Protem- hydrolysate wie Kollagen, Elastm, Weizenprotemhydrolysate und ahnliche Verbindungen, Harnstoff, Glykole und Polygly- kole. Haut-revitalisierende Wirkstoffe sind beispielsweise Vitamine, alpha-Hydroxysauren, Aminosäuren und verwandte Verbindungen. Barrieremittel sind beispielsweise Ceramide, freie Fettsauren, Sterole, Triglyceride. Selbstbrauner sind beispielsweise Dihydroxyaceton oder Erythrulose.The composition according to the invention is preferably produced on an aqueous basis and can contain further additives such as solvents, preservatives, buffers, antioxidants and / or dyes. Such additives are known per se and are listed, for example, in the CTFA Dictionary. Preferred solvents are, for example, polyglycols or polyalcohols, preferably glycerol. Preferred preservatives are, for example, phenoxyethanol, methylparaben, propylparaben, ethylparaben or butylparaben, such as are commercially available, for example, as a mixture under the brand name Phenonip®. Other additives are known to the person skilled in the art. The composition according to the invention can also be combined with active ingredients, such as sunscreens, moisturizers, skin-revitalizing active ingredients, barrier agents and / or self-tanners. Such active ingredients are known per se. Sunscreens include octyl methoxycinnamate, butyl methoxydibenzoylmethane, benzophenone, titanium dioxide, zinc oxide, and related compounds. Humectants are, for example, glycosammoglycans, hyaluronic acid and other polysaccharides, proteins and protein hydrolysates such as collagen, elastm, wheat protein hydrolysates and similar compounds, urea, glycols and polyglycols. Skin revitalizing active ingredients include vitamins, alpha-hydroxy acids, amino acids and related compounds. Barriers are, for example, ceramides, free fatty acids, sterols, triglycerides. Self-tanning agents are, for example, dihydroxyacetone or erythrulose.
Die Methoden zur Prüfung entzündeter Haut und der entsprechenden Heilungsprozesse sind an sich bekannt. Die folgen- den Anwendungsbeispiele erläutern die Erfindung.The methods for testing inflamed skin and the corresponding healing processes are known per se. The following application examples explain the invention.
Beispiel 1example 1
Tabelle 1Table 1
*gewonnen aus Soyabohnen* made from soybeans
Herstellung einer Make-up Lotion: a) Die Zusatzstoffe der in Tabelle 1 unter A) aufgeführten Substanzen werden in einem Mischer auf 70°C erhitzt und gut gemischt. Anschliessend werden die in obiger Tabelle 1 unter B) aufgelisteten Stoffe in einem Mischer bei einer Temperatur von 75 °C gemischt. b) Die Mischung der Komponenten B) wird nun dem Gemisch A unter Rühren bei 70°C langsam zugegeben und nach beendeter Zugabe auf 50°C gekühlt, homogenisiert und anschliessend auf 30°C gekühlt. Dann wird der Farbstoff zugegeben und kalt nachgerührt. Man erhält eine Make-up Lotion mit sehr guter Wirkung.Preparation of a make-up lotion: a) The additives of the substances listed in Table 1 under A) are heated in a mixer to 70 ° C. and mixed well. The substances listed in Table 1 above under B) are then mixed in a mixer at a temperature of 75 ° C. b) The mixture of components B) is then slowly added to mixture A with stirring at 70 ° C. and, after the addition has ended, cooled to 50 ° C., homogenized and then cooled to 30 ° C. Then the dye is added and stirred cold. You get a make-up lotion with a very good effect.
Beispiel 2 Tabelle 2Example 2 Table 2
*gewonnen aus Soyabohnen* made from soybeans
Herstellung eines schützend und regenerativ wirkenden Lippenstifts :Production of a protective and regenerative lipstick:
a) Der in Tabelle 2, Nr.l genannte Wax-Premix wird bei 80°C geschmolzen. Separat werden in einer Kugelmühle die Komponenten 2 bis 5 zu einer homogenen Suspension mit einer durchschnittlichen Partikelgrosse von 10-30 μm gemahlen. Diese Suspension wird zum geschmolzenen Wax-Premix gegeben und homogenisiert. Anschliessend werden die Komponenten 6 und 7 hintereinander zugegeben.a) The wax premix specified in Table 2, No. 1 is melted at 80 ° C. Components 2 to 5 are ground separately in a ball mill to form a homogeneous suspension with an average particle size of 10-30 μm. This suspension is added to the melted wax premix and homogenized. Components 6 and 7 are then added in succession.
b) Nun wird die Komponente 8 bei 80°C geschmolzen. Die Verbindungen 9 bis 13 werden auf 80°C erhitzt und der geschmolzenen Komponente 8 zugegeben, so dass eine Emulsion der unter B) aufgelisteten Komponenten erhalten wird.b) Now component 8 is melted at 80 ° C. The compounds 9 to 13 are heated to 80 ° C. and added to the molten component 8, so that an emulsion of the components listed under B) is obtained.
c) Die Emulsion der Komponenten B) wird m die in Absatz a) hergestellten Mischung bei 80°C eingerührt, gut gerührt, in Formen (Lippenstift-Formen) eingegossen und abkühlen gelassen. Der so hergestellte Lippenstift schützt die Lippen gegen schädliche Umwelteinflusse, wie Ozon, Stickoxide, UV-Strahlen etc. und Detergentien.
c) The emulsion of components B) is stirred into the mixture prepared in paragraph a) at 80 ° C., stirred well, poured into molds (lipstick molds) and allowed to cool. The lipstick produced in this way protects the lips against harmful environmental influences such as ozone, nitrogen oxides, UV rays etc. and detergents.
Beispiel 3 Tabelle 3Example 3 Table 3
*gewonnen aus Limabohnen* obtained from lima beans
Herstellung eines emulsionsähnlichen Douche-Gels für die Reinigung und Pflege der Haut: a) Die Verbindungen A) werden gut gemischt. Verbindung 7 wird in Verbindung 6 gelöst. Die erhaltene Lösung wird in die Mischung der Verbindungen A) eingerührt.Preparation of an emulsion-like douche gel for cleaning and care of the skin: a) The compounds A) are mixed well. Connection 7 is released in connection 6. The solution obtained is stirred into the mixture of compounds A).
b) Die Verbindungen der Phase C) werden hintereinander in die Verbindung 8 gelöst. Die erhaltenen Lösung wird in die unter Abschnitt a) erhaltene Mischung eingerührt.b) The compounds of phase C) are dissolved one after the other in compound 8. The solution obtained is stirred into the mixture obtained in section a).
c) Die Verbindungen der Phase D) werden in die in Abschnitt b) erhaltenen Mischung eingerührt und der pH-Wert im erhaltenen Gel auf 5.2 eingestellt.
Beispiel 4 Tabel le 4c) The compounds of phase D) are stirred into the mixture obtained in section b) and the pH in the gel obtained is adjusted to 5.2. Example 4 Table 4
*gewonnen aus Limabohnen Herstellung einer schützenden Tagescreme:* Made from lima beans Production of a protective day cream:
a) Die Komponenten der Phase A) werden gemischt und unter Mischen auf 70 °C erwärmt. Die Komponenten der Phase B) werden auf 75°C erwärmt.a) The components of phase A) are mixed and heated to 70 ° C. while mixing. The components of phase B) are heated to 75 ° C.
b) Das erhaltenen Gemisch der Phase B) wird unter Rühren dem Gemisch der erhaltenen Phase A) zugegeben. Anschliessend wird auf 50°C abgekühlt, homogenisiert und weiter auf 30°C gekühlt.b) The resulting mixture of phase B) is added to the mixture of phase A) obtained with stirring. The mixture is then cooled to 50 ° C., homogenized and further cooled to 30 ° C.
c) Die Verbindung 16 der Phase C) wird nun zugegeben und gut gemischt. Man erhält eine Tagescreme mit gutem Schutz gegen Umwelteinflüsse.
Beispiel 5 Tabelle 5c) The compound 16 of phase C) is now added and mixed well. You get a day cream with good protection against environmental influences. Example 5 Table 5
* gewonnen aus Soyabohnen * made from soybeans
Herstellung eines regenerativ wirkenden Gels: a) Die Komponenten 2 bis 6 der Phase A) werden in Wasser gelost. Die Komponenten 7 und 8 der Phase B) werden zwecks Verdickung und Neutralisierung der erhaltenen Mischung beigefugt, wobei ein Gel erhalten wird.Preparation of a regenerative gel: a) Components 2 to 6 of phase A) are dissolved in water. Components 7 and 8 of phase B) are added to thicken and neutralize the mixture obtained, a gel being obtained.
b) Die Verbindungen 9 und 10 werden in das erhaltenen Gel eingerührt. Anschliessend wird die Komponente 12 in der Komponente 11 gelost und der Phase D in das Gel eingerührt. Es wird ein klares festes Gel erhalten, welches für die intensive Behandlung müder oder leicht geschädigter Haut geeignet ist.
b) The compounds 9 and 10 are stirred into the gel obtained. Then component 12 is dissolved in component 11 and phase D is stirred into the gel. A clear, firm gel is obtained which is suitable for the intensive treatment of tired or slightly damaged skin.
Claims
1. Zusammensetzung, welche für die kosmetische und dermatologische Pflege der Haut geeignet ist, insbesondere zum Schutz der Haut gegen deren Schädigung durch eine erhöhte Ozonkonzentration in der Atmosphäre und deren Folgereaktionen, dadurch gekennzeichnet, dass diese Zusammensetzung mindestens eine Oxidoreduktase und mindestens einen Proteinase-Inhibitor enthalt, wobei das Gewichtsverhältnis der Oxidoreduktase zum Proteinase-Inhibitor vorzugsweise 20 : 1 bis 1 : 20, vorzugsweise 10 : 1 bis 1 : 10 und insbesondere 6 : 1 bis 1 : 6 beträgt.1. Composition which is suitable for the cosmetic and dermatological care of the skin, in particular for protecting the skin against its damage by an increased ozone concentration in the atmosphere and its subsequent reactions, characterized in that this composition has at least one oxidoreductase and at least one proteinase inhibitor contains, wherein the weight ratio of the oxidoreductase to the proteinase inhibitor is preferably 20: 1 to 1:20, preferably 10: 1 to 1:10 and in particular 6: 1 to 1: 6.
2. Zusammensetzung nach Anspruch 1, dadurch gekennzeichnet, dass diese den Proteinase-Inhibitor in einer Menge von mindestens 0.005 Gew.-%, vorzugsweise mindestens 0.01 Gew.-%, berechnet auf das Gesamtgewicht der Zusammensetzung, enthält.2. Composition according to claim 1, characterized in that it contains the proteinase inhibitor in an amount of at least 0.005% by weight, preferably at least 0.01% by weight, calculated on the total weight of the composition.
3. Zusammensetzung nach Anspruch 1 oder 2, dadurch gekennzeichnet, dass diese eine biotechnologisch hergestellte gereinigte Oxidoreduktase enthält.3. Composition according to claim 1 or 2, characterized in that it contains a biotechnologically produced purified oxidoreductase.
4. Zusammensetzung nach einem der Ansprüche 1-3, dadurch gekennzeichnet, dass der Proteinase-Inhibitor eine Proteinfraktion enthaltend mindestens ein Protein darstellt, welches a) aus Leguminosensamen isoliert wurde, und b) mindestens eine Bande in der Polyacrylamidgelelektro- phorese mit Natriumdodecylsulfat , c) Molekularmassen im Bereich von 3 '000 bis 30 '000 g/Mol, d) einen Gehalt an Gesamtstickstoff von 14% bis 20% und Aminostickstoff von 1 % bis 2% bezogen auf den Proteingehalt, e) Loslichkeit in Wasser und wässrigen Elektrolytlösungen und Unloslichkeit in Ethanol und Aceton, f) starke Ausfällung in wässriger Lösung nach Zusatz von Trichloressigsäure, Sulfosalicyl- säure, Pikrinsäure oder Benzethoniumchlorid, und g) Hemmung von Proteinasen, aufweist.4. Composition according to one of claims 1-3, characterized in that the proteinase inhibitor is a protein fraction containing at least one protein which a) has been isolated from legume seeds, and b) at least one band in polyacrylamide gel electrophoresis with sodium dodecyl sulfate, c ) Molecular masses in the range from 3,000 to 30,000 g / mol, d) a total nitrogen content of 14% to 20% and amino nitrogen of 1% to 2% based on the protein content, e) solubility in water and aqueous electrolyte solutions and Insolubility in ethanol and acetone, f) strong precipitation in aqueous solution after addition of trichloroacetic acid, sulfosalicyl acid, picric acid or benzethonium chloride, and g) inhibition of proteinases.
5. Zusammensetzung nach einem der Ansprüche 1-4, dadurch gekennzeichnet, dass der Proteinase-Inhibitor aus5. Composition according to any one of claims 1-4, characterized in that the proteinase inhibitor
Leguminosensamen hergestellt wurde, vorzugsweise aus Soya- oder Limabohnen.Legume seeds was produced, preferably from soybeans or lima beans.
6. Zubereitung für dermatologische und kosmetische Anwendung, welche eine Zusammensetzung nach einem der6. Preparation for dermatological and cosmetic use, which has a composition according to one of the
Ansprüche 1-5 enthält, dadurch gekennzeichnet, dass diese eine Creme, Lotion, ein Gel, eine Gesichtsmaske, ein Puder oder ein Pflaster darstellt.Contains claims 1-5, characterized in that it is a cream, lotion, a gel, a face mask, a powder or a plaster.
7. Zubereitung nach Anspruch 6, dadurch gekennzeichnet, dass deren Säurewert im pH-Bereich von 5.5 - 9 liegt.7. Preparation according to claim 6, characterized in that its acid value is in the pH range from 5.5 to 9.
8. Zubereitung nach einem der Ansprüche 1-7 in Form einer Creme, Lotion, eines Gels, einer Gesichtsmaske oder eines Puders, dadurch gekennzeichnet, dass diese 0.001 bis 2.2 Gew.-%, vorzugsweise 0.001 bis 1 Gew.-%, vorzugsweise 0.01 bis 0.5 Gew.-%, vorzugsweise 0.05 bis 0.5 Gew.-%, der Zusammensetzung nach einem der Ansprüche 1-5 als Trocken- Substanz, berechnet auf das Gesamtgewicht (100 Gew.-%) des Fertigpräparats, enthalten.8. Preparation according to one of claims 1-7 in the form of a cream, lotion, gel, face mask or powder, characterized in that it is 0.001 to 2.2% by weight, preferably 0.001 to 1% by weight, preferably 0.01 to 0.5 wt .-%, preferably 0.05 to 0.5 wt .-%, of the composition according to any one of claims 1-5 as a dry substance, calculated on the total weight (100 wt .-%) of the finished preparation.
9. Pflaster zur transdermalen Applikation einer Zusammensetzung nach einem der Ansprüche 1-5, dadurch gekenn- zeichnet, dass dieses bis zu 10 Gew.-% einer Zusammensetzung nach einem der Ansprüche 1-6, berechnet als Trockensubstanz und bezogen auf das Gesamtgewicht (100 Gew.-%) des Pflaster-Fertigpräparats, enthält. 9. plaster for transdermal application of a composition according to any one of claims 1-5, characterized in that this up to 10 wt .-% of a composition according to one of claims 1-6, calculated as dry matter and based on the total weight (100 % By weight) of the finished plaster preparation.
10. Tagescreme, After-sun-creme, Produkte für die Behandlung von trockener und wenig elastischer Haut, für Haut, welche empfindlich auf schädliche Stoffe der Umwelt reagiert, insbesondere auf Ozon, dadurch gekennzeichnet, dass diese eine Zusammensetzung nach einem der Ansprüche 1- 5 enthält.10. Day cream, after-sun cream, products for the treatment of dry and less elastic skin, for skin which is sensitive to harmful substances of the environment, in particular to ozone, characterized in that it has a composition according to any one of claims 1- 5 contains.
11. Zubereitung nach einem der Ansprüche 1-10, da- durch gekennzeichnet, dass diese im weiteren ein Sonnenschutzmittel, Feuchthaltemittel, Haut-revitalisierende Wirkstoffe, Barrieremittel und/oder Selbstbräuner enthält.11. Preparation according to one of claims 1-10, characterized in that it further contains a sunscreen, humectant, skin-revitalizing active ingredients, barrier agents and / or self-tanners.
12. Verwendung einer Zusammensetzung nach einem der Ansprüche 1-11 zur kosmetischen und dermatologischen Pflege der Haut und zur Behandlung entzündlicher Hautreaktionen, insbesondere zum Schutz gegen Schädigung durch Schadstoffe in der Atmosphäre, wie Ozon, Stickoxide, Staubpartikel, etc., UV-Strahlen und Detergentien. 12. Use of a composition according to any one of claims 1-11 for the cosmetic and dermatological care of the skin and for the treatment of inflammatory skin reactions, in particular for protection against damage caused by pollutants in the atmosphere, such as ozone, nitrogen oxides, dust particles, etc., UV rays and Detergents.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH61599 | 1999-03-31 | ||
CH61599 | 1999-03-31 | ||
PCT/CH2000/000184 WO2000059462A1 (en) | 1999-03-31 | 2000-03-30 | Composition for cosmetic and dermatological skin care |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1173145A1 true EP1173145A1 (en) | 2002-01-23 |
Family
ID=4191128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00910486A Withdrawn EP1173145A1 (en) | 1999-03-31 | 2000-03-30 | Composition for cosmetic and dermatological skin care |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1173145A1 (en) |
JP (1) | JP2002541082A (en) |
KR (1) | KR20010102559A (en) |
CN (1) | CN1345224A (en) |
AU (1) | AU3270200A (en) |
WO (1) | WO2000059462A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2811226B1 (en) * | 2000-06-05 | 2003-06-20 | Clarins Laboratoires S A S | MOISTURIZING COSMETIC COMPOSITION COMPRISING A PLANT TRYPSIN INHIBITOR |
EP1281392A1 (en) * | 2001-08-02 | 2003-02-05 | Cognis France S.A. | Cosmetic or/and pharmaceutical compositions containing plant extracts |
EP1310261A1 (en) | 2001-11-09 | 2003-05-14 | Cognis France S.A. | Use of the extract of Vigna aconitifolia in a cosmetic and/or dermopharmaceutical composition |
KR100471372B1 (en) * | 2001-12-04 | 2005-03-08 | 주식회사 태평양 | Cosmetic Composition for lifting |
WO2005084612A1 (en) * | 2004-02-24 | 2005-09-15 | Fengming Liu | The new usage of elastase inhibitors |
KR101123654B1 (en) * | 2004-05-06 | 2012-03-20 | 주식회사 래디안 | Anti-oxidative cosmetic material for the prevention of skin damage by air-pollutants |
US20060110815A1 (en) | 2004-10-13 | 2006-05-25 | Gruber James V | Personal care composition containing ozone-stressed yeast lysates |
JP2008523074A (en) * | 2004-12-07 | 2008-07-03 | アクセス ビジネス グループ インターナショナル エルエルシー | Method for removing nitric oxide and oxygen species with antioxidant fragrances |
JP4160964B2 (en) | 2005-04-01 | 2008-10-08 | 株式会社ファンケル | Sweet pea extract-containing cosmetics |
CH696659A9 (en) * | 2007-01-04 | 2007-11-15 | Labo Cosprophar Ag | Cosmetic composition for the treatment and / or prevention of skin smagllature |
TW200846017A (en) * | 2007-04-03 | 2008-12-01 | Fancl Corp | Apoptosis inhibitory agent |
CN115778837B (en) * | 2022-11-21 | 2024-04-02 | 安徽品赫生物科技有限公司 | Synergistic skin-brightening and repairing freeze-dried powder and preparation method and application thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2049728A1 (en) * | 1990-08-24 | 1992-02-25 | Kenji Kitamura | Washing composition capable of preventing and ameliorating skin irritation |
DE59209963D1 (en) * | 1991-09-13 | 2002-08-14 | Pentapharm Ag Basel | Protein fraction for cosmetic and dermatological skin care |
WO1994021222A1 (en) * | 1993-03-15 | 1994-09-29 | Nurture, Inc. | Sunblocking, emulsifying proteinaceous particulate lotion and manufacture |
FR2714599B1 (en) * | 1993-12-30 | 1996-02-09 | Oreal | Composition for fighting against aging, acting simultaneously on the superficial and deep layers of the skin, its use. |
FR2746316B1 (en) * | 1996-03-19 | 1998-06-12 | Guerlain | NEW COSMETOLOGICAL OR DERMATOLOGICAL COMPOSITIONS |
-
2000
- 2000-03-30 JP JP2000609026A patent/JP2002541082A/en active Pending
- 2000-03-30 CN CN00805716A patent/CN1345224A/en active Pending
- 2000-03-30 WO PCT/CH2000/000184 patent/WO2000059462A1/en not_active Application Discontinuation
- 2000-03-30 KR KR1020017011494A patent/KR20010102559A/en not_active Application Discontinuation
- 2000-03-30 EP EP00910486A patent/EP1173145A1/en not_active Withdrawn
- 2000-03-30 AU AU32702/00A patent/AU3270200A/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO0059462A1 * |
Also Published As
Publication number | Publication date |
---|---|
CN1345224A (en) | 2002-04-17 |
KR20010102559A (en) | 2001-11-15 |
AU3270200A (en) | 2000-10-23 |
WO2000059462A1 (en) | 2000-10-12 |
JP2002541082A (en) | 2002-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1322532C (en) | Trehalose containing cosmetic composition and method of using it | |
US4707354A (en) | Mature skin treatment and protectant compositions and methods of using same | |
DE69400337T2 (en) | Anti-aging agent that acts on the skin's upper and lower layers at the same time | |
DE69400746T2 (en) | Protective food and / or strengthening agents for simultaneous treatment of upper and lower skin layers and application | |
DE69400333T2 (en) | Cosmetic and dermatological compositions containing a combination of ceramides and linoleic acid | |
DE60104423T2 (en) | NEW COMPOUNDS OF THE FAMILY OF N-ACYLAMINOAMIDES, COMPOSITIONS AND USES THEREIN | |
DE69017333T2 (en) | Cosmetic products. | |
DE69823935T2 (en) | Epidermal isolated polypeptides and use thereof | |
DE10312259A1 (en) | A cosmetic or dermopharmaceutical composition comprising an enzyme which is insoluble in an aqueous medium and the use thereof | |
DE69500016T2 (en) | Cosmetic composition containing an associate of superoxide dismutase and porphyrins | |
JP2897973B2 (en) | Cosmetic or dermatological composition | |
EP1173145A1 (en) | Composition for cosmetic and dermatological skin care | |
DE69216188T2 (en) | Cosmetics and pharmaceuticals containing extensin | |
DE60016746T2 (en) | AQUEOUS CARRIER SYSTEMS FOR WATER-INSOLUBLE AROMATIC POLYMERS | |
JP3172753B2 (en) | Biological hyaluronic acid synthesis promoter | |
JP3278138B2 (en) | External preparation for skin | |
DE60105617T2 (en) | Composition and in particular cosmetic composition containing DHEA and / or a precursor or a derivative of DHEA in combination with at least one active against glycation | |
JP2004131401A (en) | Skin cosmetic | |
EP1566170B1 (en) | Product for skin care containing ursolic acid and gingko extract | |
JPH10212225A (en) | Wrinkle preventive | |
DE60225239T2 (en) | Caramides, compositions containing them and their uses | |
JPS61260006A (en) | Cosmetic | |
US20080076834A1 (en) | Cosmetics to promote maturation of cornified envelope and method for treatment | |
DE69728934T2 (en) | Use of 3-iodo-2-propynyl butyl carbamate in a cosmetic and / or dermatological composition as an active ingredient for the treatment of seborrhoea | |
CA1160958A (en) | Cosmetic toner formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20011031 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
17Q | First examination report despatched |
Effective date: 20021105 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20030318 |